A Phase I Dose Escalation Study of ATR Inhibitor M4344 in Combination With Niraparib in Participants With Advanced Solid Tumors Followed by Phase II Cohort Expansion in Participants With Breast Cancer With DNA Damage Response (DDR) Mutations
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Gartisertib (Primary) ; Niraparib (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors EMD Serono Research & Development Institute
- 24 Jun 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Dec 2020 New trial record